Do you follow our Newsletter? Sign up here!
The latest news
AcuCort receives renewed marketing approval for Zeqmelit in Denmark. Read more.
BioArctic receives orphan drug designation for exidavnemab in the US. Read more.
Vivesto out-licensing Apealea into Chinese. Read more.
Anocca has received regulatory approval to start a clinical study in patients with advanced pancreatic cancer. Read more.
Q-line expects to accelerate ASTar installations in 2025 and 2026, driving revenue growth. Read more.
Paxman submits a recommended takeover offer to the shareholders of Dignity. Read moreStatement from Dignitana's board of directors regarding Paxman's public takeover offer. Read more.
Oncorena receives FDA approval to initiate studies in the United States. Read more.
Genmab announces updated data from cohort B1 of the Phase I/II RAINFOL-01 study of recalcitrant sesutecan. Read more.
The board of directors of By having has decided to dismiss the company's CEO Fredrik Öhrn. Read more.
Isofol Medical is expanding its network of advisors. Read more.
Subscription period in Brain+ A rights issue of units has been initiated. Read more.
Nightingale Health establishes ADR programs in the United States. Read moreThe Swedish Financial Supervisory Authority has approved the company's prospectus. Read more.
Conference participation and presentations
Invitations
Insider trading and transactions
Summons
The latest from BioStock
» $236 billion at stake as patent collapse approaches
» Last trading day for Abliva – the company leaves Nasdaq Stockholm
» AstraZeneca buys cell therapy company for up to $1 billion
» BioStock at Swiss Nordic Bio 2025
» Annexin CEO: “Good clinical data is the key to success”